Cetuximab is the only FDA-approved EGFR-targeted therapy in HNSCC.249–251 Many compounds targeting EGFR have been developed in preclinical models, with promising response and tolerability profiles. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.